Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 80Lymphoma 35Lymphoma, Large-Cell, Anaplastic 26Hematologic Diseases 21Recurrence 18Lymphoma, Non-Hodgkin 17Lymphoma, T-Cell, Peripheral 14Lymphoma, T-Cell, Cutaneous 13Lymphoma, T-Cell 13Lymphoma, Large B-Cell, Diffuse 10Mycosis Fungoides 9Sezary Syndrome 5Neoplasms 5Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphomatoid Papulosis 4Lymphoma, Primary Cutaneous Anaplastic Large Cell 4Lymphatic Diseases 4Leukemia, Myeloid, Acute 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Lymphoma, Follicular 3Leukemia 3Dendritic Cell Sarcoma, Interdigitating 3Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Brentuximab Vedotin × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡